Nature of Operations and Basis of Presentation - Additional Information (Details) - USD ($)									3 Months Ended	7 Months Ended	12 Months Ended
	Jan. 14, 2022	Oct. 12, 2021	Mar. 19, 2021	Jan. 25, 2021	Jul. 24, 2020	Apr. 30, 2020	Mar. 18, 2020	Nov. 09, 2018	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Oct. 04, 2021
Organization Consolidation And Presentation Of Financial Statement [Line Items]
Accumulated deficit										$ 99,135,961	$ 114,509,954	$ 99,135,961
Cash and cash equivalents										5,761,568	12,710,762	5,761,568
Net cash used in operating activities											134,909	17,027,415
Proceeds from issuance of common stock, net of issuance costs											3,139,047	10,159,766
Reimbursement payment			$ 14,000,000.0
Development payments			10,000,000.0
Current liabilities										$ 6,145,546	29,109,950	$ 6,145,546
Deferred collaboration funding, current											15,825,938
Liability related to securities class action and stockholder derivative actions settlements and legal costs											$ 9,300,000
Lincoln Park
Organization Consolidation And Presentation Of Financial Statement [Line Items]
Issuance of common stock, net of issuance costs, shares											200,000	900,000
Issuance of common stock, price per share										$ 2.64	$ 2.47	$ 2.64
Proceeds from issuance of common stock gross											$ 500,000	$ 2,400,000
Common stock offering costs												2,200,000
Proceeds from issuance of common stock, net of issuance costs												$ 200,000
Remaining obligation											12,100,000
Number of shares, company may sell on any single business day						50,000
Maximum amount of Common stock at time of sale, per regular purchase						$ 1,000,000.0
Issuance of common stock for commitment fee, shares						148,148
Fair value of the commitment fee shares, recorded to general and administrative expense along with other costs						$ 400,000
Stock to be issued value on certain limitation and condition						12,100,000
Proposed Collaboration and License Agreement
Organization Consolidation And Presentation Of Financial Statement [Line Items]
Upfront non-refundable payment received			1,000,000.0
Proposed Collaboration and License Agreement | Relief Therapeutics Holding AG
Organization Consolidation And Presentation Of Financial Statement [Line Items]
Upfront non-refundable payment received				$ 1,000,000.0
Proposed Collaboration and License Agreement | Secured Loan | Relief Therapeutics Holding AG
Organization Consolidation And Presentation Of Financial Statement [Line Items]
Debt instrument, term				12 months
Debt instrument, principal amount				$ 4,000,000.0
Debt instrument, interest rate				6.00%
Collaboration Agreement | Second Development Payment
Organization Consolidation And Presentation Of Financial Statement [Line Items]
Deferred collaboration funding, current											$ 24,500,000
Collaboration Agreement | Relief Therapeutics Holding AG
Organization Consolidation And Presentation Of Financial Statement [Line Items]
Upfront non-refundable payment received				$ 1,000,000.0
Reimbursement payment			$ 14,000,000.0	$ 14,000,000.0
Potential proceeds from development payments subject to new drug application													$ 10,000,000.0
Proceeds from first tranche of development payments subject to new drug application		$ 5,000,000.0
Net profit split ratio based on territory			60.00%	60.00%
Percentage of royalty net sales received			15.00%	15.00%
Guarantee for substantive review food and drug application				$ 0
Milestone payment to be received			$ 6,000,000.0	$ 6,000,000.0
Collaboration Agreement | Relief Therapeutics Holding AG | First Development Payment
Organization Consolidation And Presentation Of Financial Statement [Line Items]
Development payments subject new drug application									$ 10,000,000.0
Collaboration Agreement | Relief Therapeutics Holding AG | Second Development Payment
Organization Consolidation And Presentation Of Financial Statement [Line Items]
Potential proceeds from development payments subject to new drug application													$ 10,000,000.0
Proceeds from first tranche of development payments subject to new drug application		5,000,000.0
Collaboration Agreement | Secured Loan | Relief Therapeutics Holding AG
Organization Consolidation And Presentation Of Financial Statement [Line Items]
Debt instrument, term				12 months
Debt instrument, principal amount				$ 4,000,000.0
Debt instrument, interest rate				6.00%
Waiver and Agreement | Relief Therapeutics Holding AG
Organization Consolidation And Presentation Of Financial Statement [Line Items]
Proceeds from second tranche of development payments subject to new drug application		5,000,000.0
Waiver and Agreement | Relief Therapeutics Holding AG | Second Development Payment
Organization Consolidation And Presentation Of Financial Statement [Line Items]
Proceeds from first tranche of development payments subject to new drug application	$ 5,000,000.0	5,000,000.0
Proceeds from second tranche of development payments subject to new drug application		$ 5,000,000.0
Waiver and Agreement | Relief Therapeutics Holding AG | Subsequent Event
Organization Consolidation And Presentation Of Financial Statement [Line Items]
Second tranche of development payment, expiry date	Jan. 14, 2022
Waiver and Agreement | Relief Therapeutics Holding AG | Subsequent Event | Second Development Payment
Organization Consolidation And Presentation Of Financial Statement [Line Items]
Proceeds from second tranche of development payments subject to new drug application	$ 5,000,000.0
Second tranche of development payment, expiry date	Jan. 14, 2022
Weighted Average | Lincoln Park
Organization Consolidation And Presentation Of Financial Statement [Line Items]
Issuance of common stock, price per share										$ 2.64	$ 2.47	$ 2.64
Maximum | Lincoln Park
Organization Consolidation And Presentation Of Financial Statement [Line Items]
Shares value might be issued under agreement						$ 15,000,000.0
Number of shares, company may sell on any single business day						100,000
Maximum | Collaboration Agreement | Relief Therapeutics Holding AG
Organization Consolidation And Presentation Of Financial Statement [Line Items]
Development payments				$ 20,000,000.0
At-the-Market Facility
Organization Consolidation And Presentation Of Financial Statement [Line Items]
Issuance of common stock, net of issuance costs, shares										1,838,957	877,107
Proceeds from issuance of common stock gross										$ 7,200,000	$ 2,800,000
Common stock offering costs										300,000	200,000
Proceeds from issuance of common stock, net of issuance costs										$ 6,900,000	2,600,000
Remained available under facility											$ 40,000,000.0
At-the-Market Facility | Weighted Average
Organization Consolidation And Presentation Of Financial Statement [Line Items]
Issuance of common stock, price per share										$ 3.9228	$ 3.1692	$ 3.9228
At-the-Market Facility | Maximum
Organization Consolidation And Presentation Of Financial Statement [Line Items]
Aggregate offering price of common stock							$ 50,000,000.0	$ 50,000,000.0
Private Placement | Directors, Officers and Employees
Organization Consolidation And Presentation Of Financial Statement [Line Items]
Issuance of common stock, net of issuance costs, shares					244,998
Issuance of common stock, price per share					$ 3.50
Proceeds from issuance of common stock, net of issuance costs					$ 900,000